Relationship between the hamilton depression rating scale and the montgomery-...sberg depression rating scale in depressed elderly: A meta-manalysis

American Journal of Geriatric Psychiatry

Volumn 15, Issue 10, 2007, Pages 899-905

  Heo, Moonseong ^a   Murphy, Christopher F ^a   Meyers, Barnett S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

depression; elderly; Hamilton Depression Rating Scale; meta analysis; Montgomery Asberg Depression Rating Scale; randomized controlled trial

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC ACCURACY; DRUG EFFICACY; FISHER EXACT TEST; FOLLOW UP; GERIATRIC PATIENT; GERONTOPSYCHIATRY; HAMILTON SCALE; HUMAN; INTERMETHOD COMPARISON; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PSYCHOLOGICAL RATING SCALE; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; AGED; COMPARATIVE STUDY; FEMALE; HOSPITALIZATION; MAJOR DEPRESSION; MALE; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME;

AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 38449111725     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e318098614e     Document Type: Article

References (29)

1. Andersen JK: Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004; 10:S18-S25
2. Perry G, Nunomura A, Hirai K, et al: Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med 2002; 33:1475-1479
3. Castellani R, Hirai K, Aliev G, et al: Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 2002; 70:357-360
4. Cedazo-Minguez A, Cowburn RF: Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Mol Med 2001; 5:254-266
5. Smith MA, Rottkamp CA, Nunomura A, et al: Oxidative stress in Alzheimer's Disease. Biochem Biophys Acta 2000; 1502:139-144
6. Hayes JD, Strange RC: Glutathione S-transferase polymorphism and their biological consequences. Pharmacology 2000; 61:154-166
7. Lovell MA, Xie C, Markesbery WR: Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's Disease. Neurology 1998; 51:1562-1566
8. Pemble S, Schroeder KR, Spencer SR, et al: Human glutathione s-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994; 300:271-276
9. Seidegard J, Vorachek WR, Pero RW, et al: Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988; 85:7293-7297
10. Ali-Osman F, Akande O, Antoun G, et al: Molecular cloning, characterization, and expression in Escherichia Coli of full-length cDNAs of three human glutathione S-transferase P1 gene variants. J Biol Chem 1997; 272:10004-10012
11. Watson MA, Stewart RK, Smith GBJ, et al: Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19:275-280
12. Bernardini S, Bellincampi L, Ballerini S, et al: Glutathione STransferase P1 *C Allelic Variant Increases Susceptibility for Late-Onset Alzheimer Disease: Association Study and Relationship with Apolipoprotein E ε4 Allele. Clin Chem 2005; 51:944-951
13. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-974
14. Folstein MF, Folstein SE, McHugh PR: Mini Mental State: a practical method for grading the cognitive state of patients for clinician. J Psychiatric Res 1975; 12:189-198
15. Cummings JL: Alzheimer's Disease. N Engl J Med 2004; 351:56-67
16. Cummings JL: The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48:S10-S16
17. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9:179-186
18. Hemmingsen A, Fryer AA, Hepple M, et al: Simultaneous identification of GSTP1 Ile105→Val105 and Ala114→Val114 substitutions using an amplification refractory mutation system polymerase chain reaction assay: studies in patients with asthma. Respir Res 2001; 2:255-260
19. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC: Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry 2004; 61:518-524
20. Li YJ, Oliveira SA, Xu P, et al: Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet 2003; 12:3259-3267
21. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA: Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006; 65:631-641
22. Hayes JD, Flanagan JU, Jowsey IR: Glutathione transferases. Annu Rev Pharmacol Toxicol 2005; 45:51-88
23. Morishima Y, Gotoh Y, Zieg J, et al: Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 2001; 21:7551-7560
24. Troy CM, Rabacchi SA, Xu Z, et al: Beta-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem 2001; 77:157-164
25. Johansson AS, Stenberg G, Widersten M, et al: Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. J Mol Biol 1998; 278:687-698
26. Scheff SW, Price DA: Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging 2003; 24:1029-1046
27. Craft S, Teri L, Edland SD, et al: Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 1998; 51:149-153
28. Murphy GM, Jr., Taylor J, Kraemer HC, et al: No association between apolipoprotein E epsilon ε4 allele and rate of decline in Alzheimer's disease. Am J Psychiatry 1997; 154:603-608
29. Hoyt BD, Massman PJ, Schtschneider C, et al: Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol 2005; 62:454-459